Genmab A/S

Total Valuation

Genmab A/S carries a market capitalization of 14.66B, placing it among publicly traded companies globally. Its enterprise value stands at 111.97B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Genmab A/S currently has 61.39M shares outstanding.

Valuation Ratios

Genmab A/S trades at a trailing price-to-earnings ratio of 131.72. The price-to-sales ratio is 27.72, and the price-to-book ratio stands at 26.38.

Enterprise Valuation

On an enterprise value basis, Genmab A/S trades at an EV/EBITDA multiple of 81.67 and an EV/FCF ratio of 105.10. The EV/Sales ratio of 28.70 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 87.00 provides insight into valuation relative to core operating earnings.

Financial Position

Genmab A/S maintains a current ratio of 2.18, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 94.17, indicating elevated leverage, while an interest coverage ratio of 8.16 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Genmab A/S posts a return on equity of 21.47 and a return on invested capital of 12.24.

Taxes

Over the trailing twelve months, Genmab A/S has paid 213.00M in income taxes, reflecting an effective tax rate of 20.60.

Stock Price Statistics

Genmab A/S's stock has gained approximately 11.85012% over the past 52 weeks. The 50-day moving average sits at 26.96, while the 200-day moving average is 29.25.

Income Statement

Over the trailing twelve months, Genmab A/S generated 3.90B in revenue and converted that into 821.00M in net income, yielding earnings per share of 1.31. EBITDA reached 1.37B, while operating income came in at 1.29B.

Balance Sheet

Genmab A/S holds 1.52B in cash and equivalents against 5.35B in total debt, resulting in a net debt position of 3.69B. Total book value stands at 4.10B, with working capital of 1.40B providing operational flexibility.

Cash Flow

Genmab A/S produced 902.00M in operating cash flow over the past twelve months. After subtracting -30.00M in capital expenditures, free cash flow totaled 872.00M - equivalent to 1.40 per share.

Margins

Genmab A/S operates with a gross margin of 93.31, reflecting its pricing power and cost economics. The operating margin of 32.99 and net profit margin of 21.05 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Genmab A/S's most recent stock split took place on May 1, 2018 with a 1:5 split ratio.

Scores

Genmab A/S posts an Altman Z-Score of 14.75, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.